Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
about
Comparison of linezolid activities under aerobic and anaerobic conditions against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolonesIn vitro activities of clindamycin, imipenem, metronidazole, and piperacillin-tazobactam against susceptible and resistant isolates of Bacteroides fragilis evaluated by kill kinetics.Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposureA new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve/MIC breakpoints and equiefficient doses of trovafloxacin and ciprofloxacin against bacteria of similar susceptibilitiesPharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model.
P2860
Q34720017-56DF82C3-458E-41FA-9496-396911FBA938Q35111853-B0CB04A5-6127-4D01-8DDE-B260B3DDA57BQ36018672-57F6939D-C1DB-481F-B59C-0FB24262267AQ39471750-6A937BC1-C4EA-4FEE-89DE-074ED9B82771Q39559370-F7B3AA22-11EF-478E-B17D-9CED2FEA72F0Q39650985-A336E255-975B-43FA-9C29-9BD50248B568Q39651777-E2FABDC7-77BE-4F77-861E-96C88FEF33D3Q39731815-7E923994-EE3E-43B2-A262-46530966AA0EQ39781591-AA31F80C-DD58-4224-ACB4-34E51F5ECA40Q41005606-09CEB761-9D5D-4CCD-B8E8-A2F24C9F1715Q41832949-6F970F79-68DA-41AB-8671-2F952B88BF88Q42014130-566740B1-B68A-4475-B8EE-8B10CAB68477
P2860
Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@ast
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@en
type
label
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@ast
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@en
prefLabel
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@ast
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@en
P2093
P2860
P356
P1476
Evaluation of activity of tema ...... vitro pharmacodynamic system.
@en
P2093
Rotschafer JC
Vance-Bryan K
Zabinski RA
P2860
P304
P356
10.1128/AAC.37.11.2454
P407
P577
1993-11-01T00:00:00Z